Skip to main content

Table 5 Patients with suspected VAP and previous exposure to statins

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

 

Statin continuation

Statin discontinuation

P

(n = 52)

(n = 41)

Age (years)

67.5 (27.0-85.0)

68.0 (46.0-90.0)

0.99

SAPS II

51.0 (18.0-109.0)

55.0 (24.0-91.0)

0.56

Gender, male (n (%))

44 (84.6)

36 (87.8)

0.66

Hospitalization prior to ICU admission (n (%))

31 (59.6)

33 (80.5)

0.03

Underlying disease(s)

 COPD (n (%))

10 (19.2)

14 (34.1)

0.10

 Chronic renal failure (n (%))

6 (11.8)

4 (9.7)

0.76

 Chronic cardiac disease (n (%))

37 (72.5)

28 (68.3)

0.66

 Diabetes mellitus (n (%))

20 (39.2)

9 (21.9)

0.07

 Cirrhosis (n (%))

0 (0.0)

2 (4.9)

0.11

Immunosuppression (excepting steroids) (n (%))

2 (4.9)

2 (3.9)

0.82

 Steroids (n (%))

5 (9.8)

3 (7.3)

0.67

 Cancer (n (%))

6 (11.8)

4 (9.8)

0.76

Nursing-home resident (n (%))

1 (1.9)

1 (2.4)

0.86

Main admission diagnosis

  

0.20

 Respiratory distress (n (%))

22 (42.3)

11 (26.8)

0.12

 Extrapulmonary sepsis (n (%))

15 (28.8)

18 (43.9)

0.13

 Neurologic failure (n (%))

4 (7.7)

6 (14.6)

0.28

 Abdominal surgery (n (%))

0 (0.0)

2 (4.9)

0.11

 Miscellaneous (n (%))

11 (21.1)

4 (9.8)

0.14

Renal failure on admission (Yes (%))

29 (55.8)

21 (51.2)

0.66

Nasogastric tube (Yes (%))

52 (100)

39 (95.1)

0.11

  1. Baseline characteristics according to statin continuation. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.
Back to article page

Critical Care

ISSN: 1364-8535